XClose

UCL-TB

Home
Menu

TB Research Programmes

IMPACT project

IMPACT

Intervening with a Manualised Package to AChieve treatment adherence in people with Tuberculosis (Jan2018 - Dec 2021). Queen Margaret University page; NIHR award page

Panacea logo

PanACEA

The Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) is a consortium that brings together scientists from 14 countries to shorten and simplify treatment for TB, through clinical trials and capacity development. UCL-TB PanACEA pagePanACEA Consortium page; EDCTP news

Panacea logo

PanACEA DECODE

 

Panacea logo

PanACEA SUDUCO

 

RID-TB logo

RID-TB

Research to Improve Detection and Treatment of Latent TB Infection (Oct 2018-Sep 2023) IGH RID-TB page

SHINE trial logo

SHINE

A randomised trial of shortening treatment for minimal (non-severe) tuberculosis (TB) in African and Indian children (July 2016-Oct 2020).    Start of trial announcement, MRC-CTU study page, Trial result announcement

 

SimpliciTB logo

SimpliciTB

SimpliciTB is a phase 3 open-label partially randomised clinical trial evaluating the efficacy, safety and tolerability of a novel and potentially shorter drug regimen (BPaMZ) for patients with drug-sensitive (DS) and drug-resistant (MDR-) pulmonary tuberculosis (2018-2022). MRC-CTU study page; TB Alliance page.

STREAM logo

STREAM Stage 2

Evaluation of a Standardised Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB (2016-2022). UCL-TB STREAM page; MRC-CTU study page; TREAT-TB page

 

TB-CHAMP

A phase III cluster randomised placebo‐controlled trial to assess the efficacy of preventive therapy in child contacts of multidrug‐resistant tuberculosis (2017-2020). MRC-CTU study page; UKRI Project page; WITS press release

TB PRACTECAL logo

TB-PRACTECAL

TB-PRACTECAL is a phase II/III clinical research project to find short, tolerable and effective treatments for people with drug-resistant tuberculosis (2016-2021).  UCL page; MSF page.

TRUNCATE TB logo

TRUNCATE-TB 

TRUNCATE-TB (Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis) is trying to speed up treatment of fully drug-sensitive TB (Duration: Sept 2013-2022) MRC-CTU study page; SPRINT-TB page

Unite4TB

UNITE4TB 

UNITE4TB  (Academia and Industry United Innovation and Treatment for Tuberculosis) is a 7-year, €185 million project that launched in July 2021, and includes 30 partners with representation from academic institutions, public organisations, and pharmaceutical companies from 13 countries.  The aim of this programme is to accelerate and improve the clinical evaluation of combinations of existing and novel drugs through Phase 2 trials. UNITE4TB website

ZeNix trial logo

ZeNix

ZeNix is a phase 3 partially-blinded, randomised trial assessing the safety and efficacy of reducing the amount of Linezolid in the Bedaquiline/Pretomanid/Linezolid (BPaL) regimen for drug-resistant TB (Nov 2017-2022). TB Alliance page; MRC-CTU page